PainReform Ltd. - Ordinary Shares (PRFX)
Competitors to PainReform Ltd. - Ordinary Shares (PRFX)
Acacia Pharma Group plc ACAC +0.00
Acacia Pharma develops medicines for improving postoperative care, including antiemetics and pain management solutions. Like PainReform, Acacia Pharma takes a research-driven approach, but its strength lies in its compelling clinical pipeline and regulatory advancements, particularly with its lead product, Barhemsys. This regulatory momentum allows Acacia to be a potent competitor in the realm of inpatient pain management, putting it ahead of PainReform.
Aptinyx Inc.
Aptinyx focuses on developing therapeutics for the treatment of chronic pain and other neurological conditions. Its unique approach towards modulation of NMDA receptors provides a distinct mechanism of action compared to PainReform’s drug delivery technologies. However, Aptinyx's competitive advantage lies in its advanced research capabilities and clinical trials, which could yield innovative solutions for pain management faster than PainReform's current offerings.
Heron Therapeutics, Inc. HRTX -2.34%
Heron Therapeutics is focused on improving pain management and postoperative care through its proprietary therapeutics. Similar to PainReform, Heron is working on innovative formulations that enhance drug delivery for pain relief. However, Heron's advantage lies in its established products such as CINVANTI for chemotherapy-induced nausea and vomiting, giving it a broader portfolio and established presence in the market.
Pain Therapeutics, Inc.
Pain Therapeutics is engaged in developing novel pharmaceutical solutions for chronic and acute pain management. They are utilizing innovative delivery methods and formulations similar to PainReform but primarily concentrate on opioids and other traditional pain management pathways. While Pain Therapeutics has a longer history and established relationships with regulatory bodies, PainReform excels in focused drug delivery technologies, allowing each company to attract different segments of the pain management market.